Product
Peptide Vaccine + Tetanus peptide
1 clinical trial
3 indications
Indication
MelanomaIndication
Metastatic MelanomaIndication
Mucosal melanomaClinical trial
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)Status: Completed, Estimated PCD: 2019-11-20